Navigation Links
Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
Date:2/12/2008

BOTHELL, Wash., Feb. 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its Board of Directors has approved a plan to further reduce operating expenses and align the company's workforce with its strategic, business and clinical development requirements.

"The workforce reduction of approximately 50 employees will enable us to drive our key clinical development and RNAi programs forward in a more efficient manner for the benefit of our shareholders," stated Steven C. Quay, M.D., Ph.D., Chairman and CEO of Nastech. "The savings by this action are estimated to be not less than $11 million during the 2008 fiscal year."

About Nastech

Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on its proprietary molecular biology-based drug delivery technologies and, through its wholly-owned subsidiary, MDRNA, Inc., based on its proprietary ribonucleic acid interference technology. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in f
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nastech Announces Promotion of Gordon Brandt, M.D. to President
2. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
3. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
4. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
5. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
6. Nastech Announces Third Quarter 2007 Financial Results
7. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
8. Nastech to Host 2007 Analyst and Institutional Investor Day
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
11. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... San Francisco, California (PRWEB) July 28, 2014 ... reach USD 604.40 billion by 2020, according to a ... scope coupled with the rising demand for effective vaccines ... to patients with unmet medical needs is expected to ... addition, the need to enhance agricultural productivity via the ...
(Date:7/28/2014)... IN (PRWEB) July 28, 2014 The ... Center, in Muncie IN, is pleased to announce that ... the National Museum of the United States Air Force. ... a year-long process that concluded this spring with an ... the Dayton, OH museum. , The National Museum ...
(Date:7/25/2014)... Trillions of bacteria live in each person,s digestive tract. ... food and stave off harmful infections, but their role ... help shed light on the role of these bacteria, ... Eric Alm recently tracked fluctuations in the bacterial populations ... findings, described in the July 25 issue of the ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 WABC Radio show ... Pet with Lorry Young will be hosting California-based Vet-Stem, ... about stem cell therapy in pets. Dr. Harman first ... of stem cell therapy for pets suffering from osteoarthritis and ... Regenerative Veterinary Medicine industry forward. , Young has invited Dr. ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3
... compounds with multiple new and existing antibiotics to create ... ... SAN DIEGO and LONDON, June 16 Mpex Pharmaceuticals ... strategic alliance for the discovery, development and,commercialization of novel medicines ...
... encourage early diagnosis of dementia ... and participation in clinical trials., Silicon ... the Internet to Transform Medical Research and ... and The University of,California, San Francisco (UCSF) today launched ...
... Planned to Initiate This Summer, SOUTH SAN ... EXEL ) announced today that the company and ... agreement on the phase 3,registration trial of XL184, ... VEGFR2, via the Special Protocol Assessment process. Exelixis,has ...
Cached Biology Technology:GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 2UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
(Date:7/25/2014)... molecular testing panel developed at UPMC greatly increases ... for patients with thyroid nodules and cancer, report ... (UPCI), partner with UPMC CancerCenter., The test, available ... diagnostic testing agencies, improved the chances of patients ... according to the study published this month in ...
(Date:7/24/2014)... leads to conflict among people around the world, a ... Health & Ecosystems: Analysis of Linkages (HEAL) Program Director ... tackle global biodiversity decline. , The harvest of wild ... and provides protein for more than a billion of ... that today,s unprecedented loss of wildlife, is bringing with ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
... far-fetched to some, but for those with arousal system disturbances ... idea that they could sense they were really outside their ... 13,000 Europeans, almost 6 percent said they have had such ... team at the University of Kentucky have studied the link ...
... and geographic data of the H5N1 avian flu virus ... found that multiple strains of the virus originated in ... of the migration routes through which the strains spread ... develop and migrate, health officials can better limit the ...
... have discovered a factor that controls blood sugar's manufacture ... its building blocks. The findings are reported in the ... Cell Press. , The study found that mice deficient ... of transcription factors, become severely lacking in the blood ...
Cached Biology News:Out-of-body experiences may be caused by arousal system disturbances in brain 2UCI scientists reconstruct migration of avian flu virus 2Blood sugar's manufacture limited by building blocks' supply 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Request Info...
...
Biology Products: